Mayo Clinic Precure - Prospective Study

NCT ID: NCT07332598

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for disease therapy.

Participants will be asked to:

* collect biological samples,
* download a mobile app,
* collect speech (voice) recordings, and
* complete surveys

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Predisposition Exposure, Environmental

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suspected Genetic Predisposition or Multi-Omics Contribution

Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution

No interventions assigned to this group

Health Control

Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Registered Mayo Clinic patient
* Able to provide informed written consent
* Able to receive mail and packages within a United States (US) state
* Able to collect and ship samples within a US state via FedEx for overnight delivery

Exclusion Criteria

* Active hematological cancer or history of a hematological cancer
* Allogeneic Bone Marrow Transplant (autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
* Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Konstantinos N. Lazaridis, M.D.

Executive Director, Center for Individualized Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Konstantinos N. Lazaridis, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brittany Burnap

Role: CONTACT

507-538-6919

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Brittany Burnap

Role: primary

507-538-6919

References

Explore related publications, articles, or registry entries linked to this study.

Thomas DC. High-volume "-omics" technologies and the future of molecular epidemiology. Epidemiology. 2006 Sep;17(5):490-1. doi: 10.1097/01.ede.0000229950.29674.68. No abstract available.

Reference Type BACKGROUND
PMID: 16906051 (View on PubMed)

Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008 Mar;5(1):4-11. doi: 10.3390/ijerph5010004.

Reference Type BACKGROUND
PMID: 18441400 (View on PubMed)

Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50. doi: 10.1158/1055-9965.EPI-05-0456. No abstract available.

Reference Type BACKGROUND
PMID: 16103423 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25-005869

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Precision PCI Registry
NCT06143709 ACTIVE_NOT_RECRUITING